Although half of patients with Type 2 diabetes (T2D) in France have blood glucose levels that are outside of their target range, an international consensus suggests that modern-day medicines now make remission possible in those recently diagnosed with diabetes (the term ‘remission’ describes a sustained metabolic improvement in T2D to near-normal levels).
Presented during the European Association for the Study of Diabetes (EASD) 2022 conference in Stockholm, a 2021 update to the previous consensus report from 2009 on diabetes remission, co-authored by the American Diabetes Association with the EASD, Diabetes UK, the International Society of Endocrinology, and the Diabetes Surgery Summit, states that “improvement of glucose levels into the normal range can occur in some people living with diabetes, either spontaneously or after medical interventions, and in some cases can persist after withdrawal of glucose-lowering pharmacotherapy. Such sustained improvement may now be occurring more often due to newer forms of treatment.”
The consensus experts believe that short-term pharmacologic therapy at the time of first presentation of T2D in adults can sometimes restore nearly normal glycemic control, allowing therapy to be withdrawn. This is on the condition that intervention is made early, within 2 years of the initial diagnosis, meaning that practitioners should be thinking about remission as an endpoint.
To read more, CLICK HERE.